Physician profile
Christopher J Robles
NPI 1982915088
$1,804.93
in general payments reported to CMS, 2019-2025
21 companies · $735 in 2025
The $735 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $242 · 2020: $51.10 · 2021: $90.56 · 2022: $136 · 2023: $132 · 2024: $418 · 2025: $735.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,285.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,285.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $317.41 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Pfizer INC. | $288.65 | 2019-2025 | |
| Abbvie INC. | $264.59 | 2021-2025 | |
| Lilly USA, LLC | $260.86 | 2023-2025 | Jardiance, Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $105.77 | 2019-2024 | Shingrix, Arexvy, Bexsero |
| Merck Sharp & Dohme LLC | $78.76 | 2019-2025 | Gardasil 9, Enflonsia, Rotateq |
| Astrazeneca Pharmaceuticals LP | $73.36 | 2025 | Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.15 | 2019-2025 | Jardiance |
| Alk-Abello, INC | $47.80 | 2025 | Neffy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $46.48 | 2025 | Xifaxan |
| Inspire Medical Systems, INC. | $42.72 | 2024 | Inspire |
| Fidia Pharma USA INC. | $29.57 | 2025 | Hymovis |
| Amarin Pharma, INC. | $29.41 | 2019 | |
| Allergan, INC. | $25.83 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $24.99 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $23.53 | 2024 | Rexulti |
| Sanofi Pasteur INC. | $20.70 | 2021 | |
| Bioventus LLC | $17.70 | 2025 | Xcell |
| Astellas Pharma US INC | $13.82 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.29 | 2019 | |
| Janssen Pharmaceuticals, INC | $12.54 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Robles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.